NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

Prior treatment

• Unlikely to initiate study drug administration before arterial puncture in those selected for EVT.
• Known prior receipt of NoNO-42 for any reason, including prior enrolment in this trial.
  • 8\) Severe comorbid illness with life expectancy less than 90 days, or likely to prevent completing 90-day follow-up.
  • 9\) Long term care facility resident or prisoner 10) Participation in another clinical trial outside of the ACT-GLOBAL platform investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding trial enrolment.

Other illness

• Any intracranial hemorrhage on qualifying imaging.

Other

• Large extent early ischemic changes/infarct in the ischemic territory on qualifying imaging.
• Known/suspected pregnancy and/or lactation.
• Systolic blood pressure \< 90 mmHg

• Confirmed or suspected acute ischemic stroke (AIS) selected for intravenous thrombolysis.
• Onset (last-known-well) time to randomization time within 4.5 hours.
• Ages ≥ 18 to ≤ 90 years.
• Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) \>5.
• Confirmed or suspected symptomatic anterior circulation intracranial occlusion. Tandem extracranial carotid and intracranial occlusions are permitted.
• Pre-stroke independent functional status in activities of daily living as judged by the enrolling physician. Patient must be living without requiring nursing care.
• Consent process completed as per national laws and regulation and the applicable ethics committee requirements.